Saturday 17 October 2026
Export HIND’s income statement to Excel — free account
Vyome Holdings, Inc.
HIND Healthcare Biotechnology
In the quarter to June 2026, revenue fell 46.0%, EPS grew 100.0% and free cash flow fell 195.0%, each against the same quarter a year earlier.
1.87
0.04
−2.09%
Follow HIND
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
116.26 | 94.13 | 23.25 | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(16.70) | (10.02) | (5.03) | (8.11) | |
P/B ratio |
2.06 | 1.79 | 1.98 | 3.65 | |
Price to Tangible BV |
2.16 | 1.86 | 2.16 | 3.96 | |
EV/Sales |
153.78 | 120.06 | 47.56 | (6.18) | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.58) | (3.68) | (4.06) | (9.38) | |
EV/FCF |
(3.58) | (3.68) | (4.06) | (9.39) | |
Quick Ratio |
4.23 | 4.10 | 1.82 | 1.84 | |
Current Ratio |
4.37 | 4.27 | 1.99 | 1.94 | |
Net Debt/EBITDA |
9.17 | 7.80 | 3.68 | 0.67 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.02 | 0.08 | (0.55) | |
Operating CF/Net income |
1.32 | 1.49 | 1.21 | 0.21 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(261.39) | (403.54) | (136.88) | (334.93) | |
Research and Development Expense of Revenue |
1,876.67% | 2,108.86% | 1,033.61% | 114.74% | |
Selling, General and Administrative Expense of Revenue |
1,351.48% | 1,511.39% | 2,721.86% | 2,440.17% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.05 | 0.04 | |
Share Based Compensation of Revenue |
40.74% | 112.97% | 281.42% | 18,710.40% | |
Graham Net Nets |
0.42 | 0.49 | 0.36 | 0.20 | |
Graham Number |
189.27 | 143.04 | 0.00 | 0.00 | |
Earnings Yield |
71,087.86% | 35,190.19% | (141.04%) | (33,312.95%) | |
Free Cash Flow Yield |
(36.97%) | (34.63%) | (50.43%) | (15.91%) | |
Revenue per Share |
0.00 | 0.00 | 0.02 | 0.01 | |
Operating CF per Share |
(0.13) | (0.21) | (0.68) | (0.64) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.13) | (0.21) | (0.68) | (0.64) | |
Cash per Share |
1.12 | 1.31 | 2.31 | 2.07 | |
Shareholders Equity per Share |
1.04 | 1.20 | 1.74 | 1.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.04 | 1.20 | 1.74 | 1.42 | |
Free Cash Flow |
(0.90) | (1.44) | (1.48) | (1.76) | |
Working Capital |
6.29 | 7.02 | 2.70 | 2.92 | |
Net Current Asset Value |
6.29 | 7.02 | 2.70 | 2.91 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | — | 0.68 | |
Average Payables |
1.21 | 1.40 | 1.13 | 2.00 | |
Average Assets |
9.10 | 8.33 | 3.94 | 6.33 | |
Average Common Equity |
6.57 | 4.64 | (0.31) | 2.70 |
Columns are period end dates · fundamentals updated 1 Oct 2026